Besivance is an ophthalmic solution used to treat bacterial conjunctivitis [1]. It is a topical antibiotic containing besifloxacin [2].
What is Besivance used for?
Besivance ophthalmic solution is indicated for the topical treatment of bacterial conjunctivitis [1]. Bacterial conjunctivitis is an infection of the eye that causes inflammation [3]. Besifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination [2].
How does Besivance work?
Besifloxacin is a fluoroquinolone antibiotic. It targets and inhibits two crucial bacterial enzymes, DNA gyrase and topoisomerase IV. By blocking these enzymes, besifloxacin prevents the bacteria from replicating their DNA and carrying out other essential cellular processes, ultimately leading to bacterial cell death [2].
When does Besivance patent exclusivity expire?
The patent exclusivity for Besivance is an important consideration for its market availability and potential for generic alternatives. Information on specific patent expiry dates for Besivance can be found through resources like DrugPatentWatch.com [4].
What are the potential side effects of Besivance?
Common side effects reported with Besivance use include eye irritation, diarrhea, and taste disturbance [1]. In clinical studies, approximately 1-3% of patients experienced these side effects. More serious but less common adverse reactions can occur [5].
Can other treatments be used for bacterial conjunctivitis?
Yes, other antibiotic eye drops and ointments are available for treating bacterial conjunctivitis. The choice of treatment may depend on the specific bacteria identified as the cause of the infection and factors such as patient age and allergies. Other fluoroquinolones, macrolides, and aminoglycosides are also used [3][6].
Who manufactures Besivance?
Besivance ophthalmic solution is manufactured by Bausch & Lomb [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2009/050809s000Besivance_label.pdf
[2] https://www.drugbank.ca/drugs/DB08829
[3] https://www.ncbi.nlm.nih.gov/books/NBK538202/
[4] https://drugpatentwatch.com/
[5] https://www.webmd.com/drugs/2/200673/besivance-ophthalmic-eye-drops/details
[6] https://emedicine.medscape.com/article/1034227-treatment